Urology
Volume 70, Issue 6, Supplement 1 , Pages S22-S26, December 2007

Is There a Better Way to Biopsy the Prostate? Prospects for a Novel Transrectal Systematic Biopsy Approach

  • Gerald L. Andriole

      Affiliations

    • Division of Urologic Surgery, Washington University School of Medicine, St. Louis, Missouri, USA
    • Corresponding Author InformationReprint requests: Gerald L. Andriole, MD, Division of Urologic Surgery, Washington University School of Medicine, 4960 Children’s Place, Campus Box 8242, St. Louis, Missouri 63110.
    • Dr. Andriole is a paid consultant to Aeterna Zentaris, Onconomica, Roche, Solvay, and Viking Medical Systems; is a study investigator partially funded by Antigenics, GlaxoSmithKline, CD Searle, and Zeneca; and has financial interests in Envisioneering and Viking Medical Systems.
  • ,
  • Travis L. Bullock

      Affiliations

    • Division of Urologic Surgery, Washington University School of Medicine, St. Louis, Missouri, USA
    • Dr. Bullock has no financial arrangement or affiliation with a corporate organization or a manufacturer of a product discussed in this supplement.
  • ,
  • Jay S. Belani

      Affiliations

    • Division of Urologic Surgery, Washington University School of Medicine, St. Louis, Missouri, USA
    • Dr. Belani has no financial arrangement or affiliation with a corporate organization or a manufacturer of a product discussed in this supplement.
  • ,
  • Erica Traxel

      Affiliations

    • Division of Urologic Surgery, Washington University School of Medicine, St. Louis, Missouri, USA
    • Dr. Traxel has no financial arrangement or affiliation with a corporate organization or a manufacturer of a product discussed in this supplement.
  • ,
  • Yan Yan

      Affiliations

    • Division of Urologic Surgery, Washington University School of Medicine, St. Louis, Missouri, USA
    • Dr. Yan has no financial arrangement or affiliation with a corporate organization or a manufacturer of a product discussed in this supplement.
  • ,
  • David G. Bostwick

      Affiliations

    • Bostwick Laboratories, Richmond, Virginia, USA
    • Dr. Bostwick is a study investigator for Bioniche, Dendreon, DiagnoCure, Endocare, Genotherapeutics, GlaxoSmithKline, and Health Tronics; and is the founder and majority shareholder in Bostwick Laboratories.
  • ,
  • Peter A. Humphrey

      Affiliations

    • Department of Pathology, Washington University School of Medicine, St. Louis, Missouri, USA
    • Dr. Humphrey has no financial arrangement or affiliation with a corporate organization or a manufacturer of a product discussed in this supplement.

The study reported here was undertaken to investigate a novel method of systematic, 3-dimensional, template-guided, transrectal ultrasound–guided prostate biopsy. The TargetScan transrectal ultrasound and prostatic biopsy system (Envisioneering Medical Technologies, St. Louis, MO) uses a stationary transrectal ultrasound probe that acquires 3-dimensional and simultaneous biplanar ultrasound imaging. With the use of prostate-specific measurements, targeted transrectal biopsy specimens of the prostate are taken. The precise location of each specimen is defined by 2 coordinates: depth in centimeters proximal from the apex of the prostate, and degree of rotation (clockwise or counterclockwise from 12 o’clock). This device has been evaluated when used with radical prostatectomy specimens. Studies on 20 radical prostatectomy specimens disclosed that simulated TargetScan biopsy correctly identified cancer in 16 (80%) prostates and high-grade prostatic intraepithelial neoplasia in 2 others. Simulated TargetScan biopsy correctly characterized 88% of prostatic octants in terms of whether or not they harbored cancer. This technique was reproducible from operator to operator, and 85% biopsy core concordance was attained when the TargetScan protocol was simulated in 2 urology residents. The TargetScan biopsy system seems to be an effective transrectal alternative to transperineal, 3-dimensional, ultrasound-guided biopsies. Its reproducibility from operator to operator suggests that it may be useful for guiding rebiopsy of specific locations within the prostate and for providing targeted focal prostate cancer therapy.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0090-4295(07)01804-3

doi:10.1016/j.urology.2007.06.1128

Urology
Volume 70, Issue 6, Supplement 1 , Pages S22-S26, December 2007